Yun Zhong
Stock Analyst at Wedbush
(2.22)
# 2,814
Out of 4,981 analysts
36
Total ratings
53.12%
Success rate
-5.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $7.00 | +471.43% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $6.76 | +314.20% | 1 | Aug 11, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $212 → $220 | $195.58 | +12.49% | 2 | Aug 8, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $9 → $8 | $4.18 | +91.39% | 2 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Reiterates: Outperform | $18 | $6.97 | +158.25% | 1 | Jun 23, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $15.74 | -4.70% | 2 | May 30, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $8 | $3.25 | +146.15% | 1 | May 27, 2025 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Outperform | $32 | $3.16 | +912.66% | 2 | May 16, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $58.82 | +19.01% | 2 | Mar 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $52.62 | +38.73% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $7.69 | +56.05% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $9.37 | +198.83% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.07 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $7.99 | +100.25% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $17.39 | +820.07% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $16.49 | +179.04% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.85 | +440.54% | 1 | May 5, 2021 |
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $7.00
Upside: +471.43%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $6.76
Upside: +314.20%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $212 → $220
Current: $195.58
Upside: +12.49%
Voyager Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.18
Upside: +91.39%
Wave Life Sciences
Jun 23, 2025
Reiterates: Outperform
Price Target: $18
Current: $6.97
Upside: +158.25%
Keros Therapeutics
May 30, 2025
Reiterates: Neutral
Price Target: $15
Current: $15.74
Upside: -4.70%
Camp4 Therapeutics
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $3.25
Upside: +146.15%
Rocket Pharmaceuticals
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.16
Upside: +912.66%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $58.82
Upside: +19.01%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $52.62
Upside: +38.73%
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $7.69
Upside: +56.05%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $9.37
Upside: +198.83%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.07
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $7.99
Upside: +100.25%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $17.39
Upside: +820.07%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $16.49
Upside: +179.04%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $1.85
Upside: +440.54%